Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients
Sophie Viaud(Université Paris-Sud), Caroline Flament(Université Paris-Sud), Mustapha Zoubir(Université Paris-Sud), Patricia Pautier(Université Paris-Sud), A. Lecesne(Université Paris-Sud), Vincent Ribrag(Université Paris-Sud), Jean‐Charles Soria(Université Paris-Sud), Virginie Marty(Université Paris-Sud), Philippe Vielh(Université Paris-Sud), Caroline Robert(Université Paris-Sud), Nathalie Chaput(Université Paris-Sud), Laurence Zitvogel(Université Paris-Sud)
Cited by 165Open Access
Abstract
Low doses of the alkylating agent cyclophosphamide (CTX) mediate antiangiogenic and immunostimulatory effects, leading to potent tumoricidal activity in association with various immunotherapeutic strategies. Here, we show in rodents and cancer patients that CTX markedly promotes the differentiation of CD4(+) T helper 17 (Th17) cells that can be recovered in both blood and tumor beds. However, CTX does not convert regulatory T cells into Th17 cells. Because Th17 are potent inducers of tissue inflammation and autoimmunity, these results suggest impact on the clinical management of various types of malignancies treated with alkylating agents and a potential need to optimize CTX-based immunotherapy in patients.
Related Papers
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
François Ghiringhelli, Cédric Menard, Pierre E. Puig et al.|Cancer Immunology Immunotherapy|2006|1.2k